Safety and efficacy of helical tomotherapy following lung-sparing surgery in locally advanced malignant pleural mesothelioma.
Adjuvant radiotherapy
Intensity-modulated radiotherapy
Local tumor control
Survival
Trimodal therapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
14
08
2023
accepted:
22
10
2023
medline:
23
11
2023
pubmed:
23
11
2023
entrez:
22
11
2023
Statut:
aheadofprint
Résumé
To assess the value of radiation therapy (RT) with helical tomotherapy (HT) in the management of locally advanced malignant pleural mesothelioma (MPM) receiving no or lung-sparing surgery. Consecutive MPM cases not undergoing extrapleural pneumonectomy and receiving intensity-modulated (IM) HT were retrospectively evaluated for local control, distant control, progression-free survival (PFS), and overall survival (OS). Impact of age, systemic treatment, RT dose, and recurrence patterns was analyzed by univariate and multivariate analysis. As a secondary endpoint, reported toxicity was assessed. A total of 34 localized MPM cases undergoing IMHT were identified, of which follow-up data were available for 31 patients. Grade 3 side effects were experienced by 26.7% of patients and there were no grade 4 or 5 events observed. Median PFS was 19 months. Median OS was 20 months and the rates for 1‑ and 2‑year OS were 86.2 and 41.4%, respectively. OS was significantly superior for patients receiving adjuvant chemotherapy (p = 0.008). IMHT of locally advanced MPM after lung-sparing surgery is safe and feasible, resulting in satisfactory local control and survival. Adjuvant chemotherapy significantly improves OS. Randomized clinical trials incorporating modern RT techniques as a component of trimodal treatment are warranted to establish an evidence-based standard of care pattern for locally advanced MPM.
Identifiants
pubmed: 37993554
doi: 10.1007/s00066-023-02174-7
pii: 10.1007/s00066-023-02174-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Rimner A, Rosenzweig KE (2012) Novel radiation therapy approaches in malignant pleural mesothelioma. Ann Cardiothorac Surg 1:457–461. https://doi.org/10.3978/j.issn.2225-319X.2012.10.07
doi: 10.3978/j.issn.2225-319X.2012.10.07
pubmed: 23977536
pmcid: 3741784
Thieke C, Nicolay NH, Sterzing F et al (2015) Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol 10:267. https://doi.org/10.1186/s13014-015-0575-5
doi: 10.1186/s13014-015-0575-5
pubmed: 26715491
pmcid: 4696301
Shavelle R, Vavra-Musser K, Lee J, Brooks J (2017) Life Expectancy in Pleural and Peritoneal Mesothelioma. Lung Cancer Int 2017:2782590. https://doi.org/10.1155/2017/2782590
doi: 10.1155/2017/2782590
pubmed: 28239496
pmcid: 5292397
Nowak AK, Jackson A, Sidhu C (2022) Management of Advanced Pleural Mesothelioma—At the Crossroads. Jco Oncol Pract 18:116–124. https://doi.org/10.1200/OP.21.00426
doi: 10.1200/OP.21.00426
pubmed: 34491782
Zalcman G, Mazieres J, Margery J, et al (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405–1414. https://doi.org/10.1016/S0140-6736 (15)01238‑6
Baas P, Scherpereel A, Nowak AK, et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397:375–386. https://doi.org/10.1016/S0140-6736 (20)32714‑8
Ricciardi S, Cardillo G, Zirafa CC et al (2018) Surgery for malignant pleural mesothelioma: an international guidelines review. J Thorac Dis 10:285–S292. https://doi.org/10.21037/jtd.2017.10.16
doi: 10.21037/jtd.2017.10.16
Spaggiari L, Marulli G, Bovolato P et al (2014) Extrapleural Pneumonectomy for Malignant Mesothelioma: An Italian Multicenter Retrospective Study. Ann Thorac Surg 97:1859–1865. https://doi.org/10.1016/j.athoracsur.2014.01.050
doi: 10.1016/j.athoracsur.2014.01.050
pubmed: 24726598
Cao C, Tian D, Park J et al (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Cancer Treat Res 83:240–245. https://doi.org/10.1016/j.lungcan.2013.11.026
doi: 10.1016/j.lungcan.2013.11.026
Tsao AS, Lindwasser OW, Adjei AA et al (2018) Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol 13:1655–1667. https://doi.org/10.1016/j.jtho.2018.08.2036
doi: 10.1016/j.jtho.2018.08.2036
pubmed: 30266660
Gomez DR, Rimner A, Simone CB et al (2019) The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol 14:1172–1183. https://doi.org/10.1016/j.jtho.2019.03.030
doi: 10.1016/j.jtho.2019.03.030
pubmed: 31125736
Waller DA, Opitz I, Bueno R et al (2021) Divided by an Ocean of Water but United in an Ocean of Uncertainty: A Transatlantic Review of Mesothelioma Surgery Guidelines. Ann Thorac Surg 111:386–389. https://doi.org/10.1016/j.athoracsur.2020.10.009
doi: 10.1016/j.athoracsur.2020.10.009
pubmed: 33223138
Minatel E, Trovo M, Polesel J et al (2014) Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Cancer Treat Res 83:78–82. https://doi.org/10.1016/j.lungcan.2013.10.013
doi: 10.1016/j.lungcan.2013.10.013
Trovo M, Relevant A, Polesel J et al (2021) Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys 109:1368–1376. https://doi.org/10.1016/j.ijrobp.2020.11.057
doi: 10.1016/j.ijrobp.2020.11.057
pubmed: 33259933
de Perrot M, Wu L, Wu M, Cho BCJ (2017) Radiotherapy for the treatment of malignant pleural mesothelioma. Lancet Oncol 18:e532–e542. https://doi.org/10.1016/S1470-2045 (17)30459‑X
Leitzen C, Wilhelm-Buchstab T, Stumpf S et al (2019) Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints. Strahlenther Onkol 195:668–676. https://doi.org/10.1007/s00066-019-01458-1
doi: 10.1007/s00066-019-01458-1
pubmed: 30915490
Müdder T, Sarria GR, Henkenberens C et al (2022) Dosimetric Comparison Between Helical Tomotherapy and Volumetric Modulated Arc Therapy in Patients With Malignant Pleural Mesothelioma. Clin Oncol 34:164–171. https://doi.org/10.1016/j.clon.2021.08.005
doi: 10.1016/j.clon.2021.08.005
Kindler HL, Ismaila N, Armato SG et al (2018) Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. JCO 36:1343–1373. https://doi.org/10.1200/JCO.2017.76.6394
doi: 10.1200/JCO.2017.76.6394
Saunders J, Ashton M, Hall C et al (2019) Pain management in patients with malignant mesothelioma: challenges and solutions. LCTT 10:37–46. https://doi.org/10.2147/LCTT.S192558
doi: 10.2147/LCTT.S192558
Clive AO, Taylor H, Dobson L, et al (2016) Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol 17:1094–1104. https://doi.org/10.1016/S1470-2045 (16)30095‑X
Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644. https://doi.org/10.1200/JCO.2003.11.136
doi: 10.1200/JCO.2003.11.136
pubmed: 12860938
Abdel-Rahman O (2017) Role of postoperative radiotherapy in the management of malignant pleural mesothelioma: A propensity score matching of the SEER database. Strahlenther Onkol 193:276–284. https://doi.org/10.1007/s00066-016-1092-7
Nelson DB, Rice DC, Mitchell KG et al (2019) Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. J Thorac Dis 11:1269–1278. https://doi.org/10.21037/jtd.2019.04.27
doi: 10.21037/jtd.2019.04.27
pubmed: 31179069
pmcid: 6531726
Shaaban SG, Verma V, Choi JI et al (2018) Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States. Clin Lung Cancer 19:e685–e692. https://doi.org/10.1016/j.cllc.2018.04.019
doi: 10.1016/j.cllc.2018.04.019
pubmed: 29803576
Heiden BT, Mitchell JD, Rome E et al (2022) Cost-Effectiveness Analysis of Robotic-assisted Lobectomy for Non-Small Cell Lung Cancer. Ann Thorac Surg 114:265–272. https://doi.org/10.1016/j.athoracsur.2021.06.090
doi: 10.1016/j.athoracsur.2021.06.090
pubmed: 34389311
Ju SG, Ahn YC, Kim Y‑B et al (2022) Dosimetric comparison between VMAT plans using the fast-rotating O‑ring linac with dual-layer stacked MLC and helical tomotherapy for nasopharyngeal carcinoma. Radiat Oncol 17:155. https://doi.org/10.1186/s13014-022-02124-0
doi: 10.1186/s13014-022-02124-0
pubmed: 36096874
pmcid: 9465858
Barsky AR, Kim MM, Maxwell R et al (2020) Initial clinical experience treating patients with palliative radiotherapy for malignant pleural mesothelioma on the HalcyonTM linear accelerator. Ann Palliat Med 9:2903–2912. https://doi.org/10.21037/apm-20-385
doi: 10.21037/apm-20-385
pubmed: 32819128
Harrabi SB, Koerber SA, Adeberg S et al (2017) Malignant pleural mesothelioma—Pleural cavity irradiation after decortication with helical tomotherapy. Rep Pract Oncol Radiother 22:402–407. https://doi.org/10.1016/j.rpor.2017.07.006
doi: 10.1016/j.rpor.2017.07.006
pubmed: 28831280
pmcid: 5554964
Fodor A, Fiorino C, Dell’Oca I et al (2011) PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlenther Onkol 187:736–743. https://doi.org/10.1007/s00066-011-2234-6
doi: 10.1007/s00066-011-2234-6
pubmed: 22037650
Simon M, Shochat T, Peled N et al (2018) Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma. Thorac Cancer 9:1470–1475. https://doi.org/10.1111/1759-7714.12860
doi: 10.1111/1759-7714.12860
pubmed: 30240138
pmcid: 6209784
Maggio A, Cutaia C, Di Dia A, et al (2016) Tomotherapy PET-guided dose escalation: A dosimetric feasibility study for patients with malignant pleural mesothelioma. Strahlenther Onkol 192:102–108. https://doi.org/10.1007/s00066-015-0901-8
Botticella A, Defraene G, Nackaerts K, et al (2017) Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation?: A planning study. Strahlenther Onkol 193:285–294. https://doi.org/10.1007/s00066-017-1108-y
Allen AM, Czerminska M, Jänne PA et al (2006) Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol 65:640–645. https://doi.org/10.1016/j.ijrobp.2006.03.012
doi: 10.1016/j.ijrobp.2006.03.012
Layer K, Layer JP, Glasmacher AR et al (2023) Risk assessment, surveillance, and nonpharmaceutical prevention of acute radiation dermatitis: results of a multicentric survey among the German-speaking radiation oncology community. Strahlenther Onkol. https://doi.org/10.1007/s00066-023-02074-w
doi: 10.1007/s00066-023-02074-w
pubmed: 37099166
pmcid: 10542714
Sardaro A, McDonald F, Bardoscia L et al (2020) Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study. Front Oncol 10:594590. https://doi.org/10.3389/fonc.2020.594590
doi: 10.3389/fonc.2020.594590
pubmed: 33425746
pmcid: 7787051
Rosenzweig KE, Zauderer MG, Laser B et al (2012) Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 83:1278–1283. https://doi.org/10.1016/j.ijrobp.2011.09.027
doi: 10.1016/j.ijrobp.2011.09.027
pubmed: 22607910
pmcid: 4359620
Arrieta O, Lozano-Ruiz F, Blake-Cerda M et al (2020) Locoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma. Thorac Cancer 11:3448–3455. https://doi.org/10.1111/1759-7714.13668
doi: 10.1111/1759-7714.13668
pubmed: 33030313
pmcid: 7705616
Nakanishi-Imai M, Murai T, Onishi M et al (2022) Survey of malignant pleural mesothelioma treatment in. Res, vol 63. Patterns of practice and clinical outcomes in tomotherapy facilities. J Radiat, Japan, pp 281–289 https://doi.org/10.1093/jrr/rrab127
doi: 10.1093/jrr/rrab127
Cho BCJ, Donahoe L, Bradbury PA, et al (2021) Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol 22:190–197. https://doi.org/10.1016/S1470-2045 (20)30606‑9
Rimner A, Hu C, Zauderer M et al (2020) A Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With Or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM) (NRG-LU006). Int J Radiat Oncol 108:e928–e929. https://doi.org/10.1016/j.ijrobp.2020.07.583
doi: 10.1016/j.ijrobp.2020.07.583